A case of severe COVID-19 with pulmonary thromboembolism related to heparin-induced thrombocytopenia during prophylactic anticoagulation therapy

Sasaki, Kosaku; Murata, Masayuki; Nakamura, Keiji; Matsumoto, Yuji; Nakashima, Yuko; Yamasaki, Sho; Ota, Azusa; Hiramine, Satoshi; Takayama, Kōji; Ikezaki, Hiroaki; Toyoda, Kazuhiro; Ogawa, Eiichi; Shimono, Nobuyuki

doi:10.1016/j.jiac.2022.05.001

Cited by 3 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the serious COVID-19 complication is thrombosis, and prophylactic anticoagulation to prevent thrombosis and reduce mortality is necessary. 111 , 112 In-hospital, the acute PE rate is higher in ICU patients than in hospitalized general wards that may reflect a more severe pro-coagulant state. Therefore, the higher rate in COVID-19 patients makes it urgent to establish the antithrombotic treatment to minimize the risk in patients.…”

Section: Introductionmentioning

confidence: 99%

COVID-19’s immuno-pathology and cardiovascular diseases

Nasab

Aghajani

Makoei

et al. 2023

Journal of Investigative Medicine

View full text Add to dashboard Cite

The pandemic of COVID-19 in worldwide causes recent millions of morbidity and mortality in all countries and is the most important challenge in the world in recent years. Coronavirus is a single-stranded RNA virus and infection with COVID-19 leads to acute respiratory distress syndrome, lung inflammation, cytokine storm, and death. The other complications include endothelial dysfunction, activation of coagulation, thromboembolic events, and vascular disease. Cardiovascular complications such as myocardial and stroke ischemia, pulmonary thromboembolism, systemic arterial, and deep vein thrombosis were reported. In this review, we presented immuno-pathological mechanisms and the effects of COVID-19 on the cardiovascular system, heart, vessels, coagulation system, and molecular glance of immuno-inflammation to the COVID-19’s pathology on the cardiovascular system.

show abstract

Section: Introductionmentioning

confidence: 99%

COVID-19’s immuno-pathology and cardiovascular diseases

Nasab

Aghajani

Makoei

et al. 2023

Journal of Investigative Medicine

View full text Add to dashboard Cite

show abstract

Significance of heparin induced thrombocytopenia (HIT) in COVID-19: a systematic review and meta-analysis

Rostami

Mansouritorghabeh

2023

J Thromb Thrombolysis

View full text Add to dashboard Cite

Heparin-induced thrombocytopenia (HIT) occurs in approximately 3% of patients receiving heparinoids. About 30–75% of patients with type 2 of HIT develop thrombosis as a result of platelet activation. The most important clinical symptom is thrombocytopenia. Patients with severe COVID-19 are among those receiving heparinoids. This meta-analysis performed to picture the current knowledge and results of published studies in this field. Three search engines were searched and 575 papers were found. After evaluation, 37 articles were finally selected of which 13 studies were quantitatively analyzed. The pooled frequency rate of suspected cases with HIT in 13 studies with 11,241 patients was 1.7%. The frequency of HIT was 8.2% in the extracorporeal membrane oxygenation subgroup with 268 patients and 0.8% in the hospitalization subgroup with 10,887 patients. The coincidence of these two conditions may increase the risk of thrombosis. Of the 37 patients with COVID-19 and confirmed HIT, 30 patients (81%) were treated in the intensive care unit or had severe COVID-19. The most commonly used anticoagulants were UFH in 22 cases (59.4%). The median platelet count before treatment was 237 (176–290) x 10 3 /µl and the median nadir platelet count was 52 (31–90.5) x 10 3 /µl. Supplementary Information The online version contains supplementary material available at 10.1007/s11239-023-02827-5.

show abstract

Heparin

2022

Reactions Weekly

View full text Add to dashboard Cite

A case of severe COVID-19 with pulmonary thromboembolism related to heparin-induced thrombocytopenia during prophylactic anticoagulation therapy

Cited by 3 publications

References 25 publications

COVID-19’s immuno-pathology and cardiovascular diseases

COVID-19’s immuno-pathology and cardiovascular diseases

Significance of heparin induced thrombocytopenia (HIT) in COVID-19: a systematic review and meta-analysis

Heparin

Contact Info

Product

Resources

About